NMD Pharma
Company

Last deal

$81.61M
Local Amount - EUR 75M

Amount

Series B

Stage

15.11.2023

Date

3

all rounds

$171.68M

Total amount

date founded

Financing round

General

About Company
NMD Pharma is a clinical-stage biotech company that develops novel treatments for neuromuscular disorders.

Industry

Sector :

Subsector :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

Leveraging their translational muscle electrophysiology platform, NMD Pharma aims to improve the quality of life for patients with neuromuscular diseases by developing first-class therapeutics. Their small molecule drugs strengthen neuromuscular transmission and muscle function, potentially benefiting a range of clinical indications and orphan human diseases. With a mission to enhance muscle function and independence for patients, NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases. Currently, they have one clinical-stage product candidate for myasthenia gravis and collaborate with renowned companies and experts in the field. Headquartered in Aarhus, Denmark, NMD Pharma has a team of over 25 drug development experts. For more information, please visit their website.
Contacts
Similar Companies
1000
MyoTherix

MyoTherix

MyoTherix is a clinical-stage drug discovery and development company for rare neuromuscular disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Union City, CA, USA

total rounds

1

total raised

$1M
GLG Pharma

GLG Pharma

GLG Pharma is a biotech company developing precision therapies for hyper-proliferative diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Jupiter, FL, USA

total rounds

2
AnnJi Pharmaceutical

AnnJi Pharmaceutical

AnnJi Pharmaceutical is developing small molecules for neurology, dermatology and inflammatory disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Taipei City, Taiwan
Vivoryon Therapeutics

Vivoryon Therapeutics

Vivoryon is a clinical stage company developing first-in-class therapies for age-related diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Halle (Saale), Germany

total rounds

7

total raised

$188.96M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$171.68M

Money Raised

Their latest funding was raised on 15.11.2023. Their latest investor Jeito Capital. Their latest round Series B

Date 
Funding Round 
Investors 
Money Raised 
Lead 
15.11.2023
5
$81.61M
Local Amount - EUR 75M
15.02.2022
5
$39.74M
Local Amount - EUR 35M
23.03.2018
4
$46.97M
Local Amount - EUR 38M
Jeito Capital

Jeito Capital

Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Paris, France

count Of Investments

20
Jeito Capital

Jeito Capital

Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Paris, France

count Of Investments

20
Roche Venture Fund

Roche Venture Fund

Roche Venture Fund invests in and developing innovative life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Basel, Switzerland

count Of Investments

83

count Of Exists

19
Inkef

Inkef

Inkef is a venture capital firm that invests in European technology and healthcare companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Amsterdam, Netherlands

count Of Investments

77

count Of Exists

13
Co-Investors
Investors
6
3

Number of lead investors

6

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B, Venture - Series Unknown
Yes
Series A, Series B, Venture - Series Unknown
No
Grant, Series A, Series B, Venture - Series Unknown
Jeito Capital

Jeito Capital

Jeito Capital is a leading global investment company focused on financing medical innovation and promoting positive societal impact.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Paris, France

count Of Investments

20

Sabine Dandiguian

Sabine Dandiguian is a Managing Partner at Jeito.

Rafaele Tordjman

Rafaele Tordjman

Managing Partner who specializes in life sciences investments. She joined Sofinnova Partners in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialisation in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Ascendis, DBV technologies [DBV:FP], Endotis, Flexion Therapeutics and Nucana Biomed. She was also on the board of Corevalve, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter and of HBI Ltd before was acquired by Meda.

current job

Jeito Capital
Jeito Capital
Roche Venture Fund

Roche Venture Fund

Roche Venture Fund invests in and developing innovative life science companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Basel, Switzerland

count Of Investments

83

count Of Exists

19
Novo Holdings

Novo Holdings

Novo Holdings is a life science investor focused on growing investment assets for scientific, social, and humanitarian purposes.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

Location

2900 Hellerup, Denmark

count Of Investments

297

count Of Exists

43

People

Founders
2
Ole Bækgaard Nielsen
Ole Bækgaard Nielsen

Ole Bækgaard Nielsen

current job

NMD Pharma
NMD Pharma

organization founded

1

Ole Bækgaard Nielsen

Claus Elsborg Olesen
Claus Elsborg Olesen

Claus Elsborg Olesen

Claus Olesen has a PhD in Physiology and Biophysics from Aarhus University. His academic work focus on structural biology and function of membrane proteins and he has several publications including two first author papers in Science and Nature. Claus has been involved in several drug development projects in both academic and industrial settings. He is co-founder of Pcovery ApS and he is CEO of Initiator Pharma. Claus serves as Business Developer at Aarhus University. He is former professional sailor and he competed in Americas Cup for Sweden in 2003 and represented Denmark at two Olympics

current job

STipe Therapeutics
STipe Therapeutics

organization founded

2

Claus Elsborg Olesen

Employee Profiles
4
Jorge A. Quiroz

Jorge A. Quiroz

Executive Vice President & Chief Medical Officer

Ole Bækgaard Nielsen

Ole Bækgaard Nielsen

CTO & Co-Founder

Thomas Holm Pedersen

Thomas Holm Pedersen

CEO

Activity

Recent News
8
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week